Clinical Trial Results:
A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's disease who are apolipoprotein Eε4 non-carriers.
Summary
|
|
EudraCT number |
2009-012748-17 |
Trial protocol |
DE AT |
Global completion date |
05 Jun 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
19 Nov 2016
|
First version publication date |
19 Nov 2016
|
Other versions |
|
Summary report(s) |
ELN115727-301(2009-012748-17)_CSR_Synopsis(Redacted).pdf |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.